	Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in TypeÂ 2 Diabetes: A Model-Based Analysis. Diabetes Ther Builes-Montaño CE, Suarez-Rodriguez AF, Alzate-Vinasco MA. PMID: 42252377 [PubMed - as supplied by publisher]
	Delphi consensus validation of an integrated climate sensitive diabetes management model for climate vulnerable health systems in Iran. Sci Rep Ghasemian A, Hooshmand E, Farkhani EM, Kouhi M, Salehi M, Tabatabaee SS, Moghri J. PMID: 42252315 [PubMed - as supplied by publisher]
	Quantifying the evidence on associated factors for diabetes-related foot complications: An umbrella review of published systematic reviews and meta-analyses. Diabetes Res Clin Pract Yang X, Guo J, Wei T, Liu P, Cai Q, Wang R, Hu Y. PMID: 42251949 [PubMed - as supplied by publisher]
	Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB. PMID: 42251860 [PubMed - as supplied by publisher]
	Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzík M, Lingvay I, Pedersen SD, Pratley RE, Jain AB, REIMAGINE 2 study group. PMID: 42251859 [PubMed - as supplied by publisher]
	Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Rosenstock J, Billings LK, Gajria R, Giorgino F, Johansen NB, Klein KR, Thamattoor UK, Buse JB, Jain AB. PMID: 42251856 [PubMed - as supplied by publisher]
	Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. PMID: 42251769 [PubMed - as supplied by publisher]
	Early Pregnancy Glycemic Testing for Prediction of Gestational Diabetes Mellitus and Large for Gestational Age Birth Weight. Diabetes Care GO MOMs Study Group*. PMID: 42251767 [PubMed - as supplied by publisher]
	Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial. Diabetes Care Leiter LA, Giugliano RP, Marston NA, De Ferrari G, Nicolau JC, Bhatia AK, Cyrille M, Park JG, Kuder JF, Murphy SA, Liu L, Walsh E, Wang H, D, Ferreira J, Gouni-Berthold I, Jensen HK, Kuusisto J, Pella D, Sattar N, Tsioufis KP, Vinereanu D, Paiva da Silva Lima G, Sabatine MS, Bohula EA. PMID: 42251764 [PubMed - as supplied by publisher]
	HTD1801 in Combination with Metformin for Type 2 Diabetes. NEJM Evid Ji L, Cheng Z, Ma J, Liu D, Zhang X, Dong X, Lin Y, Yang M, Gan S, Cai H, Wang X, Liu Y, Shi X, Liu K, MacConell L, Yu M, Liu L. PMID: 42251702 [PubMed - as supplied by publisher]
	Risk factors for mucormycosis among diabetic individuals, Bathinda, Punjab: a case-control study. BMC Infect Dis Kumbha G, Monya M, Choudhary S, Grover GS, Goyal U, Kakkar R, Saini V, Gupta V, Raj A, Sahoo SS, Krishnamoorthi S, Dikid T. PMID: 42251248 [PubMed - as supplied by publisher]
	SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden. Diabetologia Li H, Morris L, Bygdell M, Santosa A, Allansson Kjölhede E, Eeg-Olofsson K, Nyberg F, Xu Y. PMID: 42251204 [PubMed - as supplied by publisher]
	Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial. Diabetologia Parr EB, Charrouf R, Hutchison AT, Flint SA, Teong XT, Vincent AD, Bravo-Garcia AP, Siviour Z, Wittert GA, Brennan L, Devlin BL, Hawley JA, Heilbronn LK. PMID: 42251202 [PubMed - as supplied by publisher]
	Phase III maintenance telerehabilitation in elderly patients with chronic heart failure and type 2 diabetes (TELEMECHRON study). Eur J Intern Med Scalvini S, Donati V, Zanelli E, Giudici V, Viscardi L, D'Isa S, Trevisan R, Bernocchi P. PMID: 42250988 [PubMed - as supplied by publisher]
	The effect of autologous platelet rich plasma in the treatment of diabetic foot osteomyelitis patients. Chin J Traumatol Su X, Sheng W, Chen J, Li Q, Xu Q, Bai Y, Lu Y, Wang C, Yang R, Fu X, Sun X, Jiang Y. PMID: 42250976 [PubMed - as supplied by publisher]
	Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. PMID: 42250575 [PubMed - as supplied by publisher]
	High serum uric acid is linked with diabetic kidney disease progression: Evidence from Mendelian randomization analysis and animal study. Immunobiology Li X, Peng Y, Zhang W, Zhao Y, Long Z, Zhu L, Chen T, Wei X. PMID: 42250528 [PubMed - as supplied by publisher]
	Focusing on Diastolic Dysfunction to Achieve Consensus With the Term Diabetic Cardiomyopathy. Diabetes King AN, Ussher JR. PMID: 42250280 [PubMed - as supplied by publisher]
	Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review. J Am Assoc Nurse Pract Horne MP, Pollard H, Day H, Baker CL. PMID: 42250233 [PubMed - as supplied by publisher]
	The moderating role of central adiposity, sex and age, on the association between animal- and plant-based protein intake and the 20-year cumulative incidence of type 2 diabetes: the ATTICA cohort study (2002-2022). Eur J Nutr Kechagia I, Barkas F, Yannakoulia M, Liberopoulos E, Sfikakis PP, Pitsavos C, Panagiotakos D. PMID: 42250107 [PubMed - in process]

Articles 1 - 20 / 241451

Page 1 of 12073



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy